Australia markets closed

Dali Pharmaceuticalco.,Ltd (603963.SS)

Shanghai - Shanghai Delayed price. Currency in CNY
Add to watchlist
4.9700-0.2300 (-4.42%)
At close: 03:00PM CST
Currency in CNY

Valuation measures4

Market cap (intra-day) 1.09B
Enterprise value 900.17M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)16.83
Price/book (mrq)2.91
Enterprise value/revenue 13.70
Enterprise value/EBITDA -53.53

Trading information

Stock price history

Beta (5Y monthly) 0.24
52-week change 3-55.82%
S&P500 52-week change 326.49%
52-week high 315.9700
52-week low 34.8500
50-day moving average 38.9896
200-day moving average 310.3368

Share statistics

Avg vol (3-month) 313.29M
Avg vol (10-day) 35.84M
Shares outstanding 5219.7M
Implied shares outstanding 6231.31M
Float 863.56M
% held by insiders 171.06%
% held by institutions 10.49%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 423 June 2021
Last split factor 21.3:1
Last split date 308 June 2020

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -34.78%
Operating margin (ttm)-42.03%

Management effectiveness

Return on assets (ttm)-3.17%
Return on equity (ttm)-5.90%

Income statement

Revenue (ttm)65.7M
Revenue per share (ttm)0.29
Quarterly revenue growth (yoy)-58.50%
Gross profit (ttm)N/A
EBITDA -7.43M
Net income avi to common (ttm)-22.85M
Diluted EPS (ttm)-0.1000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)215.41M
Total cash per share (mrq)0.98
Total debt (mrq)23.68M
Total debt/equity (mrq)6.30%
Current ratio (mrq)3.98
Book value per share (mrq)1.71

Cash flow statement

Operating cash flow (ttm)-26.08M
Levered free cash flow (ttm)-20.38M